Home › Companies › Syndax Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Syndax Pharmaceuticals, Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 10, 2026: 6 items on Syndax Pharmaceuticals, Inc.’s Form 8-K, filed June 10, 2026: 6 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Syndax Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Syndax Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Pierre Legault | 37,294,888 | -- | -- | 21,467,975 | 8,034,588 | 63% | Not verified | — |
| Elect Director: Michael A. Metzger | 58,113,110 | -- | -- | 649,753 | 8,034,588 | 99% | Not verified | — |
| 2. Advisory vote on executive compensation | 55,688,039 | 2,985,350 | 89,474 | -- | 8,034,588 | 95% | Not verified | — |
| 3. Ratification of selection of independent registered public accounting firm | 66,603,912 | 162,947 | 30,592 | -- | -- | 99.7% | Not verified | — |
| 4. Approval of the 2026 Plan | 33,333,263 | 25,392,051 | 37,549 | -- | 8,034,588 | 57% | Not verified | — |
| 5. Approval of the 2026 ESPP | 58,661,941 | 74,047 | 26,875 | -- | 8,034,588 | 99.8% | Not verified | — |
Source: Syndax Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.
Each item below shows how the 257 asset managers that disclosed a Syndax Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Syndax Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Michael A. Metzger
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Michael A. Metzger”): 58,113,110 for, 649,753 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 20,233,720 for, 67,015 withheld, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,573,366 | 0 | 3 | 0 | For |
| State Street | 2,679,677 | 0 | 0 | 0 | For |
| Fidelity | 2,054,909 | 0 | 0 | 0 | For |
| BlackRock | 2,043,092 | 0 | 0 | 0 | For |
| TIAA | 1,440,629 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,245,615 | 0 | 0 | 0 | For |
| Charles Schwab | 718,984 | 0 | 0 | 0 | For |
| BNY Mellon | 477,196 | 0 | 0 | 0 | For |
| First Trust | 417,587 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 254,970 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| Invesco | 177,689 | 0 | 0 | 0 | For |
| Equitable | 121,726 | 0 | 0 | 54,760 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 137,313 | 0 | 0 | 0 | For |
| JPMorgan | 122,648 | 0 | 0 | 0 | For |
| Victory Capital | 111,585 | 0 | 0 | 0 | For |
| SEI | 87,106 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,637 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,506 | 0 | 0 | 0 | For |
| ProShares | 71,013 | 0 | 0 | 0 | For |
| Brighthouse | 45,836 | 0 | 0 | 12,255 | Mixed |
| AIG/SunAmerica | 57,110 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,225 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 47,079 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Pierre Legault
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Pierre Legault”): 37,294,888 for, 21,467,975 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 14,847,771 for, 5,452,890 withheld, 77 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,535,196 | 0 | 77 | 38,097 | For |
| State Street | 5,320 | 0 | 0 | 2,674,357 | Withhold |
| Fidelity | 2,054,209 | 0 | 0 | 700 | For |
| BlackRock | 2,043,092 | 0 | 0 | 0 | For |
| TIAA | 1,440,629 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 1,245,615 | Withhold |
| Charles Schwab | 718,984 | 0 | 0 | 0 | For |
| BNY Mellon | 477,196 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 417,587 | Withhold |
| Columbia Threadneedle | 254,970 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 180,000 | Withhold |
| Invesco | 177,689 | 0 | 0 | 0 | For |
| Equitable | 121,726 | 0 | 0 | 54,760 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 137,313 | 0 | 0 | 0 | For |
| JPMorgan | 122,648 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 111,585 | Withhold |
| SEI | 0 | 0 | 0 | 87,106 | Withhold |
| Tema ETF Trust | 84,637 | 0 | 0 | 0 | For |
| Lincoln Financial | 5,964 | 0 | 0 | 71,542 | Mixed |
| ProShares | 0 | 0 | 0 | 71,013 | Withhold |
| Brighthouse | 17,314 | 0 | 0 | 40,777 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 57,110 | Withhold |
| Goldman Sachs | 53,225 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 0 | 0 | 0 | 47,079 | Withhold |
Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.
47.2% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,760,404 | 3,812,965 | 0 | 0 | Mixed |
| State Street | 1,905 | 2,677,772 | 0 | 0 | Against |
| Fidelity | 2,054,209 | 700 | 0 | 0 | For |
| BlackRock | 2,043,092 | 0 | 0 | 0 | For |
| TIAA | 0 | 1,440,629 | 0 | 0 | Against |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 1,245,615 | 0 | 0 | Against |
| Charles Schwab | 718,984 | 0 | 0 | 0 | For |
| BNY Mellon | 477,196 | 0 | 0 | 0 | For |
| First Trust | 0 | 417,587 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 254,970 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 180,000 | 0 | 0 | Against |
| Invesco | 0 | 177,689 | 0 | 0 | Against |
| Equitable | 121,726 | 54,760 | 0 | 0 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 137,313 | 0 | 0 | 0 | For |
| JPMorgan | 122,648 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 111,585 | 0 | 0 | Against |
| SEI | 87,106 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,637 | 0 | 0 | 0 | For |
| Lincoln Financial | 5,964 | 71,542 | 0 | 0 | Mixed |
| ProShares | 0 | 71,013 | 0 | 0 | Against |
| Brighthouse | 29,569 | 28,522 | 0 | 0 | Mixed |
| AIG/SunAmerica | 0 | 57,110 | 0 | 0 | Against |
| Goldman Sachs | 53,225 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 47,079 | 0 | 0 | 0 | For |
Fund voting reports, all 62 managers: 9,353,839 for, 10,943,103 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| APIS CAPITAL ADVISORS, LLC | 425,108 | 0 | 0 | 0 | For |
| Vident Advisory, LLC | 998 | 0 | 0 | 0 | For |
| Keel Point, LLC | 0 | 905 | 0 | 0 | Against |
Institutional-manager reports, all 3 managers: 426,106 for, 905 against.
99.9% of fund votes cast · no official result
The 64 asset managers below reported 20,286,589 for, 12,255 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,573,369 | 0 | 0 | 0 | For |
| State Street | 2,679,677 | 0 | 0 | 0 | For |
| Fidelity | 2,054,909 | 0 | 0 | 0 | For |
| BlackRock | 2,043,092 | 0 | 0 | 0 | For |
| TIAA | 1,440,629 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,245,615 | 0 | 0 | 0 | For |
| Charles Schwab | 718,984 | 0 | 0 | 0 | For |
| BNY Mellon | 477,196 | 0 | 0 | 0 | For |
| First Trust | 417,587 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 254,970 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| Invesco | 177,689 | 0 | 0 | 0 | For |
| Equitable | 176,486 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 137,313 | 0 | 0 | 0 | For |
| JPMorgan | 122,648 | 0 | 0 | 0 | For |
| Victory Capital | 111,585 | 0 | 0 | 0 | For |
| SEI | 87,106 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,637 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,506 | 0 | 0 | 0 | For |
| ProShares | 71,013 | 0 | 0 | 0 | For |
| Brighthouse | 45,836 | 12,255 | 0 | 0 | Mixed |
| AIG/SunAmerica | 57,110 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,225 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 47,079 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.
Combines 4 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.
Syndax Pharmaceuticals, Inc.’s own tally for this item (“2. Advisory vote on executive compensation”): 55,688,039 for, 2,985,350 against, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,573,356 | 13 | 0 | 0 | For |
| State Street | 2,678,592 | 1,085 | 0 | 0 | For |
| Fidelity | 2,054,909 | 0 | 0 | 0 | For |
| BlackRock | 2,043,092 | 0 | 0 | 0 | For |
| TIAA | 1,440,629 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,245,615 | 0 | 0 | 0 | For |
| Charles Schwab | 718,984 | 0 | 0 | 0 | For |
| BNY Mellon | 477,196 | 0 | 0 | 0 | For |
| First Trust | 417,587 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 254,970 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| Invesco | 0 | 177,689 | 0 | 0 | Against |
| Equitable | 176,486 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 137,313 | 0 | 0 | 0 | For |
| JPMorgan | 122,648 | 0 | 0 | 0 | For |
| Victory Capital | 111,585 | 0 | 0 | 0 | For |
| SEI | 87,106 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,637 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,506 | 0 | 0 | 0 | For |
| ProShares | 71,013 | 0 | 0 | 0 | For |
| Brighthouse | 45,836 | 0 | 12,255 | 0 | Mixed |
| AIG/SunAmerica | 57,110 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,225 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 47,079 | 0 | 0 | 0 | For |
Fund voting reports, all 64 managers: 20,116,191 for, 178,787 against, 12,255 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 4,379,676 | 19,403 | 0 | 0 | For |
| BlackRock | 3,204,598 | 7,821 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,701,749 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 2,341,455 | 0 | 0 | 0 | For |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 2,333,573 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 2,268,423 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 2,173,230 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,161,610 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,726,437 | 0 | 0 | Against |
| Nuveen | 1,485,688 | 0 | 0 | 0 | For |
| Aisling Capital Management LP | 1,316,806 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 990,969 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 925,332 | 0 | 0 | Against |
| Palo Alto Investors LP | 864,986 | 0 | 0 | 0 | For |
| Two Sigma | 812,965 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 771,246 | 0 | 0 | 0 | For |
| Vanguard | 720,964 | 0 | 0 | 0 | For |
| Charles Schwab | 719,293 | 0 | 0 | 0 | For |
| Northern Trust | 655,657 | 11,912 | 0 | 0 | For |
| Trails Edge Capital Partners, LP | 640,898 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 614,951 | 0 | 0 | 0 | For |
| AQR | 609,914 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 545,869 | 0 | 0 | 0 | For |
| Woodline Partners LP | 496,263 | 0 | 0 | 0 | For |
| APIS CAPITAL ADVISORS, LLC | 425,108 | 0 | 0 | 0 | For |
Institutional-manager reports, all 212 managers: 40,419,562 for, 3,450,848 against, 312 abstained, 209 not voted. Showing the 25 largest; see all in the interactive database.
99.7% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Syndax Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of selection of independent registered public accounting firm”): 66,603,912 for, 162,947 against, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 20,285,485 for, 106 against, 12,255 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,573,369 | 0 | 0 | 0 | For |
| State Street | 2,679,571 | 106 | 0 | 0 | For |
| Fidelity | 2,054,909 | 0 | 0 | 0 | For |
| BlackRock | 2,043,092 | 0 | 0 | 0 | For |
| TIAA | 1,440,629 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,245,615 | 0 | 0 | 0 | For |
| Charles Schwab | 718,984 | 0 | 0 | 0 | For |
| BNY Mellon | 477,196 | 0 | 0 | 0 | For |
| First Trust | 417,587 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 254,970 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| Invesco | 177,689 | 0 | 0 | 0 | For |
| Equitable | 176,486 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 137,313 | 0 | 0 | 0 | For |
| JPMorgan | 122,648 | 0 | 0 | 0 | For |
| Victory Capital | 111,585 | 0 | 0 | 0 | For |
| SEI | 87,106 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,637 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,506 | 0 | 0 | 0 | For |
| ProShares | 71,013 | 0 | 0 | 0 | For |
| Brighthouse | 45,836 | 0 | 12,255 | 0 | Mixed |
| AIG/SunAmerica | 57,110 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,225 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 47,079 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 88,610,027 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 6.29% |
| 2 | State Street | 3.02% |
| 3 | Fidelity | 2.32% |
| 4 | BlackRock | 2.31% |
| 5 | TIAA | 1.63% |
| 6 | Manager Directed Portfolios | 1.54% |
| 7 | FRANKLIN STRATEGIC SERIES | 1.41% |
| 8 | Charles Schwab | 0.81% |
| 9 | BNY Mellon | 0.54% |
| 10 | First Trust | 0.47% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | State Street | 4.96% |
| 2 | BlackRock | 3.63% |
| 3 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3.05% |
| 4 | Eversept Partners, LP | 2.64% |
| 5 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 2.63% |
| 6 | Hood River Capital Management LLC | 2.56% |
| 7 | FRANKLIN ADVISERS INC | 2.45% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.44% |
| 9 | BNP Paribas Asset Management Holding S.A. | 1.95% |
| 10 | Nuveen | 1.68% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Kynam Capital Management LP | 9.62% | DEF14A |
| Entities affiliated with BlackRock, Inc. | 7.61% | DEF14A |
| STATE STREET CORPORATION | 6.39% | 13G |
| The Goldman Sachs Group | 6.30% | DEF14A |
| Vanguard Capital Management | 5.03% | 13G |
| Point72 Asset Management, L.P. | 2.24% | 13G |
| Michael A. Metzger | 2.22% | DEF14A |
| Luke J. Albrecht | 0.83% | DEF14A |
| Keith A. Goldan | 0.57% | DEF14A |
| Dennis G. Podlesak | 0.35% | DEF14A |
Percentages above are of 88,610,027 shares outstanding, as reported by Syndax Pharmaceuticals, Inc. on its Form 10-Q dated April 27, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Syndax Pharmaceuticals, Inc.’s 10-Q dated April 27, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At Syndax Pharmaceuticals, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 257 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,553 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Syndax Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2026.
Syndax Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.